Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin after acute myocardial infarction (high HF risk)
CTR20210834Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in myocardial infarction (MI), heart failure (HF), cardiac morbidity, sponsored by Boehringer Ingelheim. Started Apr 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)heart failure (HF)cardiac morbidity
Beyond the preview
Go deeper on CTR20210834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210834.